A J Welton1, M R Vickers, J A Cooper, T W Meade, T M Marteau. 1. Medical Research Council Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, St Bartholomew's and Royal London Hospital School of Medicine and Dentistry, London ECIM 6BQ. a.j.welton@mds.qmw.ac.uk
Abstract
OBJECTIVE: To investigate whether including a placebo arm in a clinical trial of hormone replacement therapy influenced women's stated willingness to participate. DESIGN: Quasirandomised, interview based study. SETTING: 10 group practices in the Medical Research Council's General Practice Research Framework. PARTICIPANTS: 436 postmenopausal women aged 45-64 who had not had a hysterectomy. MAIN OUTCOME MEASURES: Stated willingness to enter a trial and reasons for the decisions made. RESULTS: Of 218 women told about the trial without aplacebo arm, 85 (39%) indicated their willingness to enter compared with 65 (30%) of the 218 women told about the trial with the placebo arm (P=0.06). Part of this difference was due to explicit reluctance to take a placebo. Altruism and personal benefit were the reasons most frequently given for wanting to take part in a trial. The reasons most frequently cited for not wanting to take part were reluctance to restart periods, not wanting to take unknown or unnecessary tablets, or not wanting to interfere with present good health. CONCLUSION: For preventive trials the inclusion of a placebo arm may reduce patients' willingness to participate.
RCT Entities:
OBJECTIVE: To investigate whether including a placebo arm in a clinical trial of hormone replacement therapy influenced women's stated willingness to participate. DESIGN: Quasirandomised, interview based study. SETTING: 10 group practices in the Medical Research Council's General Practice Research Framework. PARTICIPANTS: 436 postmenopausal women aged 45-64 who had not had a hysterectomy. MAIN OUTCOME MEASURES: Stated willingness to enter a trial and reasons for the decisions made. RESULTS: Of 218 women told about the trial without a placebo arm, 85 (39%) indicated their willingness to enter compared with 65 (30%) of the 218 women told about the trial with the placebo arm (P=0.06). Part of this difference was due to explicit reluctance to take a placebo. Altruism and personal benefit were the reasons most frequently given for wanting to take part in a trial. The reasons most frequently cited for not wanting to take part were reluctance to restart periods, not wanting to take unknown or unnecessary tablets, or not wanting to interfere with present good health. CONCLUSION: For preventive trials the inclusion of a placebo arm may reduce patients' willingness to participate.
Entities:
Keywords:
Biomedical and Behavioral Research; Empirical Approach
Authors: D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings Journal: Ann Intern Med Date: 1992-12-15 Impact factor: 25.391
Authors: M J Stampfer; G A Colditz; W C Willett; J E Manson; B Rosner; F E Speizer; C H Hennekens Journal: N Engl J Med Date: 1991-09-12 Impact factor: 91.245
Authors: Shellie D Ellis; Alain G Bertoni; Denise E Bonds; C Randall Clinch; Aarthi Balasubramanyam; Caroline Blackwell; Haiying Chen; Michael Lischke; David C Goff Journal: Contemp Clin Trials Date: 2006-09-01 Impact factor: 2.226
Authors: Dona E C Locke; Melanie Chandler Greenaway; Noah Duncan; Julie A Fields; Andrea V Cuc; Charlene Hoffman Snyder; Sherrie Hanna; Angela Lunde; Glenn E Smith Journal: J Prev Alzheimers Dis Date: 2014-12
Authors: Shaun Treweek; Pauline Lockhart; Marie Pitkethly; Jonathan A Cook; Monica Kjeldstrøm; Marit Johansen; Taina K Taskila; Frank M Sullivan; Sue Wilson; Catherine Jackson; Ritu Jones; Elizabeth D Mitchell Journal: BMJ Open Date: 2013-02-07 Impact factor: 2.692